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Lockdown and our national supply  
of blood products
To the Editor: Our generation finds itself in an unprecedented 
situation, as coronavirus disease 2019 (COVID-19) causes wide-
spread changes to everyone’s lives. Our healthcare system has faced 
adversity in various forms, but this current crisis brings new and 
more difficult challenges.
An important aspect of medical treatment is the use of blood 
products. The availability of these products is reliant on voluntary 
donations and appropriate use by clinicians. A large proportion 
of donations are made from the elderly, perhaps at greatest risk 
from COVID-19, and educational institutions, now closed through 
isolation polices. Data from other countries highlight social distancing 
and self-isolation as important steps in slowing down transmission of 
coronavirus.[1] However, these measures will drastically reduce the 
number of blood donations, unless different collection strategies are 
employed.
South Africa already has limited blood products, with the South 
African National Blood Service (SANBS) and Western Cape Blood 
Service (WCBS) needing to collect more than 3 500 units of blood 
every day to maintain adequate stocks. Less than 1% of the population 
regularly donate blood, and more than 30% of donors are under 
25 years of age, demonstrating the burden on blood collection when 
schools and universities are closed. The high incidence of HIV, trauma 
and chronic illness places tremendous demand on an already limited 
supply, with several areas still having limited access to blood products – 
all these problems will persist during the COVID-19 pandemic.
There are ongoing efforts to improve appropriate and responsible 
use of these limited and life-saving blood products through patient 
blood management (PBM) systems. There is now an even greater 
need to implement and support these efforts.[2] In the light of 
current events, we can expect a dramatic decrease in the number of 
donations, and subsequently a mismatch in supply and demand. The 
blood products available for our hospitals and clinics will therefore 
rapidly decrease. This will continue for months, and we consider that 
the following are important:
• Healthcare professionals should be aware of this pending problem 
and implement PBM programmes, ensuring that blood products 
are only used when necessary, through diagnosis and management 
of anaemia, of which the most common and treatable pre-operative 
cause remains iron deficiency.[2]
• Patients should generally only be transfused if alternative measures 
have failed and they are symptomatic from anaemia, or in cases 
of emergency. Single-unit transfusions should be used as far as 
possible. Healthcare workers should be made aware of transfusion 
threshold data showing that very few patients require blood 
transfusions if their haemoglobin concentration is >7 g/dL.[3-5]
Hospital managers and transfusion committees must take proactive 
roles in directing PBM activities in their hospitals.
• The public should be made aware of this problem and make 
concerted efforts to donate blood out of their normal routine.
• The blood transfusion services should be supported by the 
Department of Health and public forums to ensure continued 
supply of products.
Addressing these issues will ensure that lives are saved and appropriate 
care delivered in these difficult times. Failure to address these issues 
timeously will result in a blood product supply crisis in which 
patients will suffer with increased mortality.
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